- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04986501
Clinical Evaluation of MucoPEG™ for Xerostomia (CEMPEG)
The purpose of this study is to evaluate the effectiveness of the oral rinse comparing to MucoPEG™ and Biotene®.
This is a randomized open-label crossover study with 42 patients receiving treatment. Patients will be randomly assigned to receive either the MucoPEG™ or the Biotene® Dry Mouth Gentle Oral Rinse in the first period. Patients will use the assigned oral rinse two times a day for two weeks. Patients will switch to the other treatment after a wash-out period of one week.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80923
- ColoradoENT
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts University School of Dental Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Must have read, understood and signed an informed consent prior to entering the study.
- Must be 18 years of age or older
- Good general and mental health with, in the opinion of the investigator or their medically qualified designee, no clinically relevant or significant abnormalities found on examination of the oral cavity or in their medical history.
- Participant with a Challacombe Scale score of 1 or higher
- Participant agrees not to eat, drink, chew tobacco, chew gum, smoke, brush or floss their teeth for 2 hours prior to study visits
- Participant agrees not to use any oral care products or any type of breath mint or lozenges for 2 hours prior to study visits
- Participant agrees not to consume any food or liquid during the study visits, except for what is provided by the study research staff (e.g., water and treatments A and B during evaluation periods)
- Participant agrees to using clinical oral care supplies provided by the investigators and no other products during the entire study
- Understands and is willing and able to comply with all study procedures and restrictions
Exclusion Criteria:
- Women who are pregnant or intending to become pregnant over the course of the study, or who are found to have a positive urine pregnancy test at the Screening Visit
- Women who are breast-feeding
- Participant is currently undergoing radiotherapy and/or chemotherapy.
- Any condition the investigator identifies that may impede the participant's ability to properly participate in the study. For example, Alzheimer's Disease
- Participant with untreated oral mucosal disease which in the opinion of the investigator could interfere with the study. For example, presence of oral ulceration.
- Evidence of gross intra-oral neglect or need for extensive dental therapy
- Denture wearer (complete dentures)
- Participant on systemic parasympathetic medications (e.g. pilocarpine) for treating dry mouth, but the dose requirement of which is unstable
- Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or to any of their stated ingredients
- Participation in another clinical study (including studies of cosmetic products) or in receipt of an investigational drug within 14 days of the screening visit
- Previous participation in this study
- Recent history (within one year prior to screening visit) of alcohol or other substance abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MucoPEG
Arm being compared to against Biotene
|
Experimental
|
Active Comparator: Biotene
Arm being compared against MucoPEG
|
Active Comparator
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Analogue Scale (VAS)
Time Frame: Prior to product use, first day of treatment period, after the last dose of the product used and on the final day of treatment period.
|
To demonstrate the effectiveness of MucoPEG is better than that of Biotene Dry Mouth Gentle Oral Rinse in relieving xerostomia.
Effectiveness will be addressed using the Visual Analogue Scale (VAS).
(VAS), where 0 is "Not Dry at All" and 10 is "Very Dry"
|
Prior to product use, first day of treatment period, after the last dose of the product used and on the final day of treatment period.
|
Dry Mouth Relief Questionnaires (DMRQ)
Time Frame: 2 weeks
|
To demonstrate the effectiveness of MucoPEG is better than that of Biotene Dry Mouth Gentle Oral Rinse in relieving xerostomia.
Effectiveness will be addressed using the Dry Mouth Relief Questionnaires (DMRQ).
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Product Use Questionnaire (PPUQ)
Time Frame: 2 weeks
|
To demonstrate effectiveness of MucoPEG in treating symptoms of dry mouth to that of Biotene.
Effectiveness will be assessed using dry mouth Product Use Questionnaire (PPUQ).
|
2 weeks
|
Product Performance and Attributes Questionnaire (PPAQ)
Time Frame: 2 weeks
|
To demonstrate effectiveness of MucoPEG in treating symptoms of dry mouth to that of Biotene.
Effectiveness will be assessed using dry mouth Product Performance and Attributes Questionnaire (PPAQ)
|
2 weeks
|
Number of participants with treatment-related adverse events as evaluated by the Principal Investigator
Time Frame: 2 weeks
|
To evaluate the clinical safety of MucoPEG.
Patient reported outcomes will be evaluated by the Principal Investigator.
|
2 weeks
|
Change in Xerostomia using the Dry Mouth Inventory (DMI) questionnaire.
Time Frame: 2 weeks
|
To examine change in Xerostomia using the Dry Mouth Inventory (DMI).
Using a scale from "Disagree (0)" to "Strongly agree (3)"
|
2 weeks
|
Visual Analogue Scale (VAS)
Time Frame: 2 hours and 1 week of use
|
To assess the effectiveness of MucoPEG in relieving xerostomia.
Effectiveness will be addressed using the Visual Analogue Scale (VAS).
Where 0 is "Not Dry at All" and 10 is "Very Dry"
|
2 hours and 1 week of use
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: To be determined To be determined, DDS, Study Site
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SB-MU-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Xerostomia
-
Cathrine RahbekDanish Cancer Society; DLHM - Danish Society for Mouth and Throat Cancer; Danish...Active, not recruitingXerostomia Following Radiotherapy | Xerostomia Following in Neck Ore Head After CancersurgeryDenmark
-
Institute of Oncology LjubljanaUniversity Medical Centre Ljubljana; University of Ljubljana; Blood Transfusion...Not yet recruitingXerostomia Following RadiotherapySlovenia
-
Catholic University of the Sacred HeartSunstar Italiana SRL.CompletedXerostomia | Xerostomia Following RadiotherapyItaly
-
Qazvin University Of Medical SciencesImam Khomeini HospitalCompletedRadiation-Induced XerostomiaIran, Islamic Republic of
-
Bedford Hospital NHS TrustUnknownXerostomia | Xerostomia Due to Radiotherapy | Xerostomia Due to Hyposecretion of Salivary Gland
-
Institut de Terapia Regenerativa TissularUnknownXerostomia Due to RadiotherapySpain
-
MeiraGTx, LLCActive, not recruitingRadiation-induced XerostomiaUnited States, Canada
-
Thomas KuhntVerband Deutscher DruckkammerzentrenTerminatedRadiation-induced XerostomiaGermany
-
Laboratoires CARILENEDERMSCAN-PHARMASCAN GROUP in charge of data analysisCompleted